Jump Financial LLC Purchases 5,707 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Jump Financial LLC raised its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLSFree Report) by 171.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 9,029 shares of the company’s stock after acquiring an additional 5,707 shares during the period. Jump Financial LLC’s holdings in Apellis Pharmaceuticals were worth $343,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. First Horizon Advisors Inc. raised its position in shares of Apellis Pharmaceuticals by 69.0% during the 3rd quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock valued at $25,000 after acquiring an additional 265 shares during the last quarter. National Bank of Canada FI bought a new stake in shares of Apellis Pharmaceuticals during the 2nd quarter valued at $33,000. Stephens Consulting LLC bought a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at $38,000. Focused Wealth Management Inc bought a new stake in shares of Apellis Pharmaceuticals during the 2nd quarter valued at $45,000. Finally, US Bancorp DE raised its position in shares of Apellis Pharmaceuticals by 391.2% during the 1st quarter. US Bancorp DE now owns 1,110 shares of the company’s stock valued at $56,000 after acquiring an additional 884 shares during the last quarter. Institutional investors own 90.43% of the company’s stock.

Insider Activity

In other news, CAO James George Chopas sold 864 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $66.81, for a total value of $57,723.84. Following the completion of the transaction, the chief accounting officer now owns 40,128 shares in the company, valued at approximately $2,680,951.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Jeffrey Eisele sold 438 shares of Apellis Pharmaceuticals stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $66.81, for a total transaction of $29,262.78. Following the completion of the transaction, the insider now owns 72,650 shares in the company, valued at $4,853,746.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO James George Chopas sold 864 shares of Apellis Pharmaceuticals stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $66.81, for a total value of $57,723.84. Following the transaction, the chief accounting officer now owns 40,128 shares of the company’s stock, valued at approximately $2,680,951.68. The disclosure for this sale can be found here. Insiders sold 68,826 shares of company stock worth $4,301,015 in the last quarter. Corporate insiders own 7.50% of the company’s stock.

Apellis Pharmaceuticals Stock Performance

APLS opened at $67.75 on Tuesday. The company has a market capitalization of $8.03 billion, a price-to-earnings ratio of -12.90 and a beta of 0.93. The business’s 50-day moving average price is $63.22 and its two-hundred day moving average price is $49.56. The company has a debt-to-equity ratio of 0.40, a current ratio of 4.29 and a quick ratio of 3.76. Apellis Pharmaceuticals, Inc. has a 1 year low of $19.83 and a 1 year high of $94.75.

Analyst Upgrades and Downgrades

APLS has been the subject of a number of recent analyst reports. Oppenheimer upped their price objective on shares of Apellis Pharmaceuticals from $75.00 to $79.00 and gave the company an “outperform” rating in a research report on Tuesday, January 30th. Wedbush raised their price objective on Apellis Pharmaceuticals from $39.00 to $60.00 and gave the stock a “neutral” rating in a research note on Friday, January 12th. Wells Fargo & Company downgraded Apellis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $67.00 to $54.00 in a research note on Thursday, December 14th. Jefferies Financial Group raised Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the stock from $68.00 to $80.00 in a research note on Monday, February 5th. Finally, Citigroup dropped their price objective on Apellis Pharmaceuticals from $70.00 to $67.00 and set a “buy” rating on the stock in a research note on Friday, December 15th. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $74.73.

Read Our Latest Research Report on APLS

Apellis Pharmaceuticals Company Profile

(Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA).

See Also

Institutional Ownership by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.